Introduction: Knowledge of Brazilian scientists profile is important to understand the factors that influence the behavior of those interested in developing science. Objective: To outline the profile of Brazilian physiotherapist researchers, permanent, or collaborator professors of PhD programs in physiotherapy. Methods: Study of documentary analysis with scientometric techniques on physiotherapist data in Brazilian doctors associated professors in PhD programs. To identify the professors, the Sucupira and Lattes Platforms were used, and the research areas were categorized according to COFFITO. Data on the research area, the number of orientations, publications and impact factor average (JCR) were analyzed by 1-way ANOVA test (p < 0.05), and a collaboration network was built using Gephi 0.9.1 software. Results: Nine institutions of higher education in Brazil have a PhD in physiotherapy. A total of 119 professors are associated with UFMG (20.2%), UFSCAR (17.6%), UFRN (13.4%), and UNINOVE (10.9%). The median number of doctors graduated by the professors was 1.0 (0.0 -6.0) and in publications in the period was 4.6 (2.4 -8.4). The main study designs were observational 71 (59.7%), and the main research area was neurofunctional 25 (21.0%). The collaboration between UFSCAR and UFMG professors is strengthened. Conclusion: There are few specific doctoral programs for physiotherapists in Brazil. The majority of them are concentrated in the southeast region, and the professor staff have very heterogeneous characteristics related to the duration of the programs, the nature of the institution, or the affiliation of the professor.
<div><strong>Introdução</strong>: O Linalol é um metabólito secundário, componente de óleos essenciais aromáticos de origem vegetal, sendo uma das substâncias mais importantes na indústria farmacêutica; é utilizado como fixador de fragrâncias, mas também pela medicina popular para efeitos anti-inflamatórios, analgésicos, hipotensores, vasorrelaxantes, antinociceptivos e atividade antimicrobiana. Além dessas propriedades, tem ações hipnóticas, hipotérmicas e sedativas. <strong>Objetivo</strong>: Sistematizar o conhecimento acerca dos efeitos biológicos já conhecidos do Linalol e apresentar as futuras possibilidades para este monoterpeno. <strong>Metodologia</strong>: A revisão sistemática da literatura conta com artigos publicados no período de 2001 a 2014, cuja busca foi realizada no primeiro semestre de 2014, a partir das palavras-chave e seus respectivos correlatos nos idiomas inglês e espanhol, nas bases de dados on-line PUBMED, MEDLINE e LILACS. Incluíram-se artigos que abordavam o uso de Linalol para diferentes fins. Houve ainda a inclusão de teses e dissertações que atendessem aos critérios de inclusão. Quanto aos excluídos, contam-se aqueles encontrados em duplicidade e os encontrados além do período de publicação estipulado. <strong>Resultado</strong>: Encontrou-se um total de 2.734 artigos relacionados à palavra-chave Linalol nos diferentes idiomas. A partir da leitura dos resumos e aplicação dos critérios de exclusão, selecionaram-se 37 artigos para discussão. <strong>Conclusão</strong>: O Linalol cria uma nova possibilidade terapêutica em diversas enfermidades, quando aplicado a órgãos e tecidos diferenciados. Poderá ser forte aliado do sistema cardiovascular, na redução e controle da pressão arterial, ainda tão difícil de ser alcançado, no controle da dor, seja crônica, inflamatória ou neuropática, e resultados recentes mostram o grande potencial do Linalol para uso na terapia anticâncer. Assim sendo, é necessária a realização de outros trabalhos, na intenção de melhor esclarecer os mecanismos e ações já conhecidos e buscar novas</div><div>aplicações para este material.</div>
Hypertension is a major public health concern globally and a risk factor for cardiovascular diseases (CVD). 1 The number of hypertensive adults increased from 594 million in 1975 to 1.13 billion in 2015, mainly in low-income and middle-income countries. 2 Moreover, in Brazil, approximately one quarter of the adult population are reported to have hypertension. 3 Globally, CVD was responsible for approximately 17.5 million deaths in 2012. If current trends continue, the annual number of deaths will increase to 22.2 million by 2030. 4 Frequently, hypertension is associated with metabolic disorders, functional or structural alterations of target organs, which are aggravated by behavioural risk factors, such as smoking, obesity, excessive salt intake and aging. The most common form of hypertension is "essential hypertension"; however, the causes remain unknown. 5,6 The treatment of hypertension includes some classes of drugs, including: beta-blockers, diuretics, angiotensin-converting enzyme inhibitors, angiotensin II receptor blockers, calcium channel
ResumoIntrodução: a toxina botulínica tipo A, utilizada com segurança e eficácia, promove relaxamento muscular com efeito em 24-72 horas, melhora clínica entre 7-10 dias e duração de 3-6 meses. A paralisia cerebral, síndrome caracterizada por distúrbios no controle motor e postura, apresenta alterações musculoesqueléticas, deformidades ósseas e contraturas. Objetivo: a sistematização do conhecimento sobre o uso da toxina botulínica no ganho de funcionalidade em crianças com paralisia cerebral tipo espástica, através de uma revisão da literatura com publicações entre os anos 2003 e 2013. Metodologia: foram selecionados 15 artigos para discussão. A toxina botulínica tem um valor preditivo para o ganho de funcionalidade e desenvolvimento da criança. As variáveis descritas foram: ação da toxina botulínica no ganho de amplitude de movimento articular, melhora das habilidades funcionais, qualidade de marcha e independência locomotora. Conclusão: a toxina botulínica é poderosa fonte de redução da espasticidade, aumento da mobilidade articular, alongamento muscular, melhora do tônus e funcionalidade, seja na marcha ou uso dos membros, o que traz ganho no repertório de habilidades da função motora com maior independência funcional e de locomoção. Palavras-chave: Toxina Botulínica Tipo A. Paralisia Cerebral. Espasticidade Muscular. AbstractIntroduction: the botulinum toxin used safely and effectively promotes muscle relaxation in effect in 24-72 hours clinical improvement 7-10 days and 3-6 months duration. Cerebral palsy syndrome characterized by disturbances in motor control and posture, presents musculoskeletal abnormalities, bone deformities and contractures. Objective: to systematize the knowledge on the use of botulinum toxin in functionality gain in children with cerebral palsy spastic type. Methodology: literature review with the period 2003 to 2013. Articles Access to Medline and Lilacs, using the descriptors: botulinum toxin type A, cerebral palsy and spastic gait with its correlates in English and Spanish. Included work on the gain in functionality after botulinum toxin and excluded those who associated the toxin with other diseases or therapies. Results: after adoption of the inclusion and exclusion criteria, 15 articles were selected for discussion. Botulinum toxin has a predictive value for the child's functionality and development gain. The variables to be described were: action of botulinum toxin in range of motion gain joint, improvement of functional skills, quality of gait and locomotor independence. Conclusion: botulinum toxin is powerful source of reducing spasticity, increased joint mobility, muscle stretching with range of motion gain, improves tone and functionality, whether in motion or use of members, which brings gain in the repertoire of skills of motor function with greater functional independence and mobility.
Taking into account the increasing use of cyclodextrins (CDs) to overcome drawbacks of drugs like antihypertensive, complex formation with of CDs seems to be a good pharmaceutical strategy to improve stability, solubility, bioavailability and reduction of side effects, thus facilitating the control of hypertension. The main objective of this short communication is to demonstrate the antihypertensive potential of complexed compounds with β-cyclodextrins and their clinical applications. This short communication identified and illustrated that β-cyclodextrin-based systems are promising sources that provide improved pharmacokinetic and formulation conditions, and important applications have been established by many research groups, optimizing β-CDs derivative systems for oral drug therapy, especially in hypertension.
scite is a Brooklyn-based organization that helps researchers better discover and understand research articles through Smart Citations–citations that display the context of the citation and describe whether the article provides supporting or contrasting evidence. scite is used by students and researchers from around the world and is funded in part by the National Science Foundation and the National Institute on Drug Abuse of the National Institutes of Health.
hi@scite.ai
334 Leonard St
Brooklyn, NY 11211
Copyright © 2024 scite LLC. All rights reserved.
Made with 💙 for researchers
Part of the Research Solutions Family.